Introduction
New regimens of multiple-drug chemotherapy coupled with irradiation of the nervous system and the intrathecal administration of methotrexate have greatly improved the prognosis for children with acute lymphoblastic leukaemia (ALL).' -4 The length of remission and survival have increased and the incidence of overt central nervous system (CNS) involvement by ALL has decreased drarnatically.4 Many children have discontinued all treatment for periods approaching eight years without evidence of relapse.5 Between February 1970 and September 1974 we treated both children and adults with ALL using a regimen which incorporates three combinations, each of four drugs, in a predetermined cyclical rotation, together with prophylactic treatment of the CNS.6 We report here the results obtained at 31 March 1975.
Patients and methods
Forty-two previously untreated patients with an apparently unequivocal diagnosis of ALL or acute undifferentiated leukaemia were included in the study and no exclusions were made either iriitially or retrospectively. There were 28 male and 14 female patients and their ages ranged from 2 to 43 vears (mean 8 years, median 5 years); 31 patients were Europeans and 11 were of Indian origin (table I). ALL was diagnosed by the examination of Romanowskystained films of peripheral blood and bone-marrow; cytochemical stains (PAS, Sudan Black, myeloperoxidase) were performed on some but not all patients. Electron microscopical examination of leukaemic cells and tests for markers of T-or B-lymphocytic origin8 were not performed when most of these patients were diagnosed, but these tests were carried out on some of the patients who later relapsed. Demonstration of T-lymphocytic markers was not used as a basis for exclusion of patients since most patients remained in remission and their leukaemic cells could not therefore be tested. The first patient was admitted to the study on 2 February 1970 and the 42nd patient on 30 September 1974; the maximum and minimum follow-up times were therefore 62 and 6 months respectively. Haemoglobin (g/dl):
6-8-9 .9
Platelets (x 10/l1): The scheme of treatment is illustrated in fig 1 and but this practice was discontinued when the myelosuppressive effects of colaspase during remission induction were shown.9 Consolidation and maintenance treatment was bv intermittent pulses of treatment, using the combinations cyclophosphamide, vincristine, cytarabine, and prednisolone (COAP)'0; prednisolone, vincristine, methotrexate, and mercaptopurine (POMP)"; and cytarabine, colaspase, daunorubicin, thioguanine (CART).6 These combinations exploit known synergies between various antileukaemic drugs, avoid excessive overlap of drug toxicities, and ensure that all the most effective drugs are administered repeatedly. Treatment was given in five-day courses with nine-day treatment-free intervals. Most patients were admitted to hospital for induction therapy and thereafter attended the outpatient clinic once every 14 days. Drugs requiring intravenous administration (vincristine, daunorubicin) were given at the clinic, but intramuscular injections (cytarabine, methotrexate, colaspase) were commonly given at home by the family doctor, district nurse, or relatives. The doses of antileukaemic drugs other than vincristine, prednisolone, and colaspase could often be increased during maintenance treatment. For patients who became recurrently pancytopenic the treatment-free interval was lengthened from 9 to 16 days but full doses were given. During the maintenance phase the children continued to attend school and the adults returned to work. Subcutaneous cerebrospinal-fluid (CSF) reservoirs were inserted as a means of administering extended intrathecal prophylactic treatment6 7 12 in eight cases but when the efficacy of conventional CNS prophylaxis was established4 the prophylactic use of reservoirs was discontinued."' A radiation dose of 2400 rads (linear accelerator or cobalt machine) was administered to the skull through laterally opposed fields in 12 fractions. The first lumbar puncture was performed immediately after the induction of remission (fig 1) , CSF was obtained for cytological examination, and methotrexate (7.5 mg/M2) was instilled. Five more doses of methotrexate were administered by the intrathecal route during the period of cranial irradiation ( fig 1) and when necessary the doses of cyclophosphamide and cytarabine given in the COAP combination, which was being administered concurrently, were reduced to permit the completion of this intrathecal treatment.
Cyclic maintenance treatment was continued (fig 1) until relapse occurred, or until 130 weeks (21-years) after bone-marrow remission had first been shown. During maintenance treatment the bone marrow was examined at least every six weeks. At the end of the 130th week the bone marrow was examined once more and a lumbar puncture was carried out, with sampling of fluid for cytological examination and the instillation of methotrexate (7-5 mg/M2). Thereafter blood counts were performed every four weeks and bone marrow examinations every eight weeks for one year, every six and 12 weeks respectively in the second year, and every 12 and 24 weeks in the third year.
Ten additional patients treated by this regimen were not included in the study because they had received previous treatment: six had had relapses of their disease three in the bone marrow, one in the CNS, and two in both. The results of treatment in these 10 patients are included for comparison with those in the untreated patients. 23 and 28 months after beginning the regimen, and one died in complete remission from subacute measles encephalitis. The 10th patient had received no cranial irradiation and had relapsed in the CNS alone. He was treated with intrathecal methotrexate and cytarabine plus cranial irradiation and received the new regimen for 25 months. After nine months off treatment he remained in haematological and CNS remission.
Discussion
Treatment for ALL is assessed, firstly, by its capacity to induce and maintain haematological and CNS remission and by the length of survival during and after treatment; secondly, by the hazards of the treatment weighed against its efficacy; and finally, by the expense, demands on medical and laboratory man-hours, and convenience for the patients and their relatives, which vary according to social, economic, and geographic factors.
The induction of remission in 41 out of 42 patients (980' ) is gratifying but in a larger series a lower rate might be expected. We compared the results of remission maintenance treatment with those in the UKALL-I trial4 and in studies V-VII of the Memphis group.3 Most of the statistical comparisons were made at two years, because at two and a half years the number of patients in our series was small and the survival curve was beginning to be unstable (SE ± 10o/). At two years, comparing the numbers of patients who had neither relapsed nor died in these three series, there was no statistically significant difference. The small difference found favoured our current regimen (fig 2) . At two and a half years a few more deaths and slightly fewer relapses had occurred in our series than in UKALL-I. At first sight, therefore, the COAP/POMP/CART regimen seems to possess no significant advantage, while it is slightly more unpleasant for the patients, more troublesome for medical staff, and significantly more costly than treatment by either the UKALL-I or the Memphis regimens. A third of our patients, however, were aged 10 years or more and a quarter were over 15 years old. Age above 10 years is usually considered to be a prognostically unfavourable feature, and when this is taken into account the possible advantage suggested in fig 2 may nausea, and subjective difficulty in breathing after the first injection only of colaspase in every course of CART treatment. These reactions are unpleasant and potentially dangerous, but they did not occur when the initial injection was administered subcutaneously. They are unlikely to be allergic but might be due to the rapid deamination of a normal plasma content of asparagine with a transient rise in blood ammonia when the colaspase is administered intravenously.
Our results suggest that the COAP/POMP/CART regimen merits further study, particularly in adults with ALL and in patients of any age with high blast cell counts at presentation. Its value in cases of documented T-cell ALL is as yet uncertain. It is not significantly superior when given to children with ALL who have no adverse prognostic features, though our data do not exclude the possibility that such superiority may exist.
Summary
There is wide individual variation in the number of millimoles of calcium bound per gram of albumin in the serum. Individual regression coefficients for serum calcium concentration on serum albumin concentration have been determined in 62 people (25 of our own patients and 37 reported by others). The 95 percentile range was 0-007-0 053 mmol/g, with a median value of 0-025 mmol/g. Accordingly, it is not valid to "correct" a person's measured serum total calcium concentration for variations in serum albumin concentration using an average regression coefficient. Rather, the individual's own regression coefficient must be used. A tourniquet test seems to be the simplest technique for determining this value. Even then, precise interpretation of an individual's corrected serum calcium concentration is possible only when an appropriate reference range for corrected serum calcium concentration has been established. Such an appropriate reference range must be determined from an adequate number of normal people using the individual's own correction factor in each case.
Introduction
Most routine laboratories can estimate the serum total calcium concentration very accurately, but since total calcium is the sum of ionised (50°,), protein bound (40%0), and complexed (10%' ) calcium fractions, and it is only the ionised fraction that is physiologically important, the estimation falls short of clinical requirements. Since albumin is the main (or sole) protein to which calcium is bound changes in serum albumin concentration will change the serum total calcium concentration. Hence numerous correction factors, relating measured serum calcium concentration to specific gravity, total protein, and serum albumin concentrations, have been developed. '-5 We report here the wide individual variation in the regression coefficients of serum calcium concentration on serum albumin concentration found in 25 hospital inpatients and in a further 37 patients reported by others. We consequently question the validity of "correcting" an individual's measured serum calcium concentration by an average correction factor. Alternative approaches to the problem are discussed.
Patients and methods
Concentrations of both serum total calcium and serum albumin were measured by dye-binding methods on the Technicon SMA 12/60. Serum total calcium was measured using the standard Technicon cresolphthalein complexone method with a typical between-batch coefficient of variation of 18°,. Serumi albumin estimations were performed by a modified bromocresol green method with increased linearity6 and with a typical between-batch coefficient of variation of 2 000 Purified human albumin (Dade) was used as a standard.
Mean regression coefficient of calcium on albumin-Blood was collected without stasis from 163 fasting healthy laboratory personnel aged from 17 to 65 years. These ambulant subjects were not on any medication and blood was collected without stasis and separated within two hours. Data were also collected from 163 hospital inpatients with a variety of medical and surgical conditions but without renal impairment (serum creatinine concentration < 150 ,umol/l
